arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

BioAtla, Inc.

BCAB

$3.42 ▲ +0.13 (+3.95%) at close

8 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

BioAtla, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $10.1B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 129.5% ↗

FCF / Share $-0.02 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-59.61M

↑ +14.6% —

FCF / Share Free cash flow per share

$-0.02

↑ +44.7% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

100

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	29.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	44.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	5.8% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	0.7% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	14.6% Fair ↑ Fair Improving Year-over-year change in net income	43.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-15.9% Weak ↑ Weak Improving Year-over-year change in net income	-11.6% Weak ↑ Weak Improving Year-over-year change in net income	-166.1% Weak Weak Year-over-year change in net income	-20.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	44.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	32.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	6.3% Fair Fair Year-over-year change in free cash flow	-29.0% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
FCF / Net Income (x)	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.32x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	129.5% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-409.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-145.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-47.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-36.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-11.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-428.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-141.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-108.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	164.7% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+998%)	—	-174.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1265%)	-59.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-494%)	-45.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-402%)	-17.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-214%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Interest Coverage (x)	—	—	—	—	-32146.67x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-21.67x Weak Weak Operating income divided by interest expense Optimal: > 5x	-17.34x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-7.12M	$-49.05M	$-111.47M	$-215.51M	$-244.98M	$-238.60M	$-3.70M	$-10.86M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	—	—	—	—	$0.00	—	—	—
Basic EPS, GAAP (USD)	$-0.02	$-0.03	$-0.05	$-0.05	$-0.06	—	—	—
Free Cash Flow per Share (USD)	$-0.02	$-0.03	$-0.04	$-0.05	$-0.04	—	—	—
Book Value per Share (USD)	$-0.01	$0.00	$0.03	$0.08	$0.12	$0.13	—	—
Tangible Book Value per Share (USD)	$-0.01	$0.00	$0.03	$0.08	$0.12	$0.13	—	—
Basic Weighted Avg Shares (shares)	2.94B	2.43B	2.39B	1.95B	1.73B	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$-13.91M	$36.69M	$88.06M	$197.30M	$227.48M	$208.42M	—	—
Total Equity (USD)	$-36.19M	$14.27M	$70.67M	$180.34M	$210.82M	$209.97M	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	$300.00K	—	—	—
Depreciation Expense (USD)	$373.00K	$925.00K	$1.22M	$1.20M	$1.33M	$1.01M	$860.00K	—
Net Income, GAAP (USD)	$-59.61M	$-69.78M	$-123.46M	$-106.48M	$-95.40M	$-35.85M	$-29.86M	—
Operating Cash Flow (USD)	$-48.20M	$-71.94M	$-104.02M	$-90.42M	$-62.21M	$-36.33M	$-9.64M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters

BioAtla, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BCAB with peers